SEOUL, South Korea, Oct. 24, 2018 /PRNewswire/ — The Korea Ginseng Association reported that the annual October Korean Ginseng festivals, total 16 of them this year, are successfully being held across the nation.
A Korean Ginseng Festival
Among the 16 festivals, Anseong World Organic Ginseng Summit, 2018 Kaesong Ginseng Festival, Geumsan Insam Festival, Seosan Ginseng Farmers Market, Hongcheon Luxury GInseng and Korean Beef festival, Eumseong Ginseng Festival, and Jeungpyeong Ginseng Festival have successfully finished.
At these festivals, the increased number of foreign tourists garnered attention, reflecting the influence of Hanryu and growing global interests in the Korean Ginseng.
At the Geumsan Insam Festival, interactive booths that provided opportunity to experience traditional Korean medicine market, brewing new sprout ginseng liquor, and soap-making grabbed visitors’ interests.
‘Anseong World Organic Ginseng Summit 2018’ operated an exhibition that provided education about and samples of ginseng; other activities such as Organic Ginseng Hunt, making ginseng plant pots, and food courts were also popular.
Hongcheon Luxury Ginseng and Korean Beef festival connected the farmers with consumers directly. The cooking area is located next to the market space to provide a space for the visitors to buy and enjoy good quality products at affordable prices. Traditional game of tug-of-war and cooking contest also entertained the visitors.
The Korean Ginseng festival will continue until the end of October in other regions:
The above-mentioned festivals are awaiting tourists and visitors.
The Korea Ginseng Association’s vice-chairman Han-Seung-Hun says, “Through these Korean Ginseng festivals happening across the region, I hope visitors can become familiar with the world-famous Korean Ginseng.“
TAIPEI, Taiwan, Oct. 24, 2018, /PRNewswire/ — TaiwanJ Pharmaceuticals, a specialty pharmaceutical company dedicated to the development and commercialization of small molecules for unmet medical needs, recently announced the results of phase II clinical trial of JKB-122 for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) that demonstrated significant improvement on relevant diagnosis and biomarkers from the JKB-122 treated subjects after the completion of 12-week study.
JKB-122 is a small molecule and a long-acting TLR4 antagonist showing anti-fibrotic, immuno-modulating, and anti-inflammatory effects for the treatments of chronic liver diseases including Non-Alcoholic Fatty Liver Disease (NAFLD), Autoimmune Hepatitis (AIH), and Non-Alcoholic Steatohepatitis (NASH).
A total of 121 subjects in Taiwan participated in a phase 2, randomized, multiple-dose, double-blind, placebo-controlled study of JKB-122 for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD), focusing on both drug efficacy and safety. All subjects were divided into 3 testing groups, respectively receiving once daily 5 mg, 35 mg JKB-122, and placebo during the study. The entire testing period lasts 12 weeks.
According to the unblinded results, the phase 2 study has successfully achieved its primary endpoint with the statistical significance (P<0.05) in efficacy. In 35 mg JKB-122 treated group, there were 36.9% of subjects showing statistically significant reduction by over 30% or recovering to normal value in alanine aminotransferase (ALT) with reduction of liver fat content monitored by Magnetic Resonance Spectroscopy (MRS); mean change of ALT, -18.3 IU, P=0.0067. In addition, the secondary endpoints of the trial were achieved, with 70% of subjects showing statistically significant reduction by over 30% in aspartate aminotransferase (AST); mean change of AST, -8.2 IU, P=0.0235. The whole group showed statistically significant reduction with triglyceride (TG) recovered to normal; mean change of TG, -26.0 IU, P=0.0225. There were 33% of subjects showing liver fat content (by MRS) reduced over 30%; liver fat content (by MRS) showed statistically significant reduction; mean change of liver fat content, -4.2 IU, P=0.0005. High-density lipoproteins (HDL) showed statistically significant increase; mean change of HDL, +2.7 IU, P=0.0084. Tissue inhibitor of metalloproteinase 1 (TIMP-1) showed statistically significant reduction; mean change of TIMP-1, -37.8 IU, P=0.0391. Moreover, the drug JKB-122 is safe and well-tolerated in this study.
For JKB-122, TaiwanJ Pharmaceuticals is planning to file the phase III clinical study application to TFDA in Q2, 2019.
NAFLD is the most common chronic liver disease. Statistics have shown that the prevalence rate of NAFLD is around 25% worldwide, 24% in Europe, and 27% in Asia. Most importantly, NAFLD is the initial stage of a serial subsequent liver diseases of Non-Alcoholic Steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. In addition, there are no effective treatments for these liver diseases. According to the analytical reports of TechNavio, Deutsche Bank, and ITRI’s IEK, the NAFLD/NSAH drug market is expected to be US$ 3.9 billion by 2020, and reach to US$ 38.2 billion with 23% CAGR by 2030.
AboutTaiwanJ Pharmaceuticals
TaiwanJ Pharmaceuticals Co., Ltd is a specialty pharmaceutical company dedicated to the development and commercialization of small molecules for unmet medical needs such as NAFLD/NASH, chronic organ inflammation of metabolic, autoimmune and infectious etiologies. In addition, immune modulating therapies for cancers are being pursued.
For additional information on TaiwanJ, please visit the Company’s website at www.taiwanj.com for English http://www.taiwanj.com/pages/page_index_en, where you can review the Company’s SEC filings, press releases, announcements and events.
Forward-Looking Statement
Various statements in this release concerning TaiwanJ’s future expectations constitute “forward-looking statements” within the meaning of the Taiwan Securities and Exchange Act. These statements include words such as “may,” “expects,” “anticipates,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of TaiwanJ to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. In addition, any forward-looking statements represent TaiwanJ’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. TaiwanJ does not assume any obligation to update any forward-looking statements unless required by law.
BEIJING, Oct. 23, 2018 /PRNewswire/ — China Electronics Data Service Co., Ltd. (“CECD”) and WuXi AppTec announced today to set up a joint venture, CW Data, to offer one-stop big data solutions for the healthcare sector. Based on hospital medical and prescription data, CW Data will provide healthcare data solutions for pharmaceutical companies, biotechnology companies, payers, providers, policy makers, healthcare professionals and other life science industry organizations, thereby further promoting the innovation and development of the China’s healthcare ecosystem and benefiting more Chinese patients.
Relying on CECD’s National healthcare big data platform and National healthcare big data security platform and strictly complying with the National Healthcare Big Data Safety and Supervision laws and regulations to ensure multi-dimensional data security, CW Data will integrate with WuXi AppTec’s unmatched deep domain expertise in drug discovery and development to leverage highly innovative data collection, data mining and data analytics, provide end to end technology solutions and services ranging from drug discovery and development to post-marketing drug efficacy evaluation and drug distribution, and assist customers to deeply explore the needs of Chinese patients, so that more new drugs and therapies with urgent medical needs will be launched earlier in China. CW Data will build and lead the next generation of healthcare big data analytics.
“The establishment of CW Data is an important cornerstone for CECD into healthcare analytics and big data. Healthcare big data is one of the key national strategic resources. The development of various big data applications will bring profound changes in the healthcare sector. WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company. The future of CW Data is tremendous. CW Data will combine big data, cloud computing, artificial intelligence and other cutting-edge technologies to connect hospitals, insurance, disease, prescriptions, clinical, and genomics data to provide real world evidence and business insights to domestic and foreign biotechnology companies, drug distributors and medical device companies. Finally, achieve the vision of CECD – ‘Making people healthier and happier’“. said Li Shifeng, Chairman of CECD.
“This collaboration is a significant move for WuXi AppTec to strengthen our capability in medical big data industry and provide more effective solutions for the whole healthcare ecosystem with the efficient integration of hospitals’ medical data, drug research and development resources.” said Dr. Ge Li, Chairman and CEO of WuXi AppTec, “Through this collaboration, we will enable more doctors, scientists and healthcare companies by exploring more precise patient needs and more insightful healthcare data analytics, to achieve the dream that every drug can be made, every disease can be treated.”
Andy Liu, CEO of CW Data and a 20 year veteran of the healthcare industry said: “This is indeed a very special joint venture. The combination of CECD and Wuxi AppTec enables CW Data to take a leadership role in healthcare big data analytics and to drive changes that will ultimately benefit the patients. We look forward to building the future and working with other healthcare big data, AI, cloud and software companies to achieving our goals.”
About CECD
China Electronics Data Service Co., Ltd. (CECD) is a national healthcare big data group company led by China Electronics Corporation under the guidance of the National Health Commission of PRC. CECD is a National High-Tech Enterprise and Zhongguancun High-Tech Enterprise, it adheres to the principle of “safety first, data services, platform operation, ecological development” to structure two core capabilities: “Safety “and “Intelligence”.
Relies on the national team of security and informatization – China Electronics Corporation, CECD forged a full life cycle data security system with the tri-alliance of security integrated system, management and control system, and safety contingency system, based on securities of nature, process, industrial control, and data.
CECD is the main operator of the National Healthcare Big Data Center and Industrial Park (Fuzhou), the only implementation unit of the National Development and Reform Commission (hereinafter referred to NDRC) key program “Internet + Healthcare”, the co-construction unit of NDRC Healthcare Big Data Engineering Laboratory, and the Secretary General unit of the Healthcare Big Data Development and Information Security Committee of China Health Information Association (China Healthcare Big Data Industrial Alliance). As the chief initiator, CECD is the key funder of Shanghai Data Exchange Corp. Also, it established CEC Healthcare Fund and its management company – CEC Data and Finance Investment Management Co., Ltd., to build the ecosystem of healthcare big data.
About WuXi AppTec
WuXi AppTec (603259, SH) is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, drug R&D and medical device testing, WuXi platform is enabling over 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi’s dream that “every drug can be made, every disease can be treated.”
SINGAPORE, Oct. 23, 2018 /PRNewswire/ — AWAK Technologies (AWAK), a pioneering medical technology company focused on dialysis using regeneration technology for end-stage renal disease, today announced positive preliminary results from a recently completed Phase I study investigating the safety of AWAK PD in dialysis treatment for patients with End Stage Renal Disease (ESRD) led by the Singapore General Hospital (SGH).
AWAK PD
A world-first, the AWAK PD is a wearable and ultra-portable peritoneal dialysis (PD) system that incorporates AWAK’s patented sorbent technology to disrupt the way in which peritoneal dialysis is currently administered. The AWAK PD is a compact device that weighs less than 2 kg and enables dialysis to be performed “on-the-go”, overcoming the challenge of long hours of therapy and connection to large-size dialysis machines in hospitals and clinics currently faced by renal patients.
The sorbent technology regenerates and reconstitutes used dialysis fluid into fresh fluid while removing the uremic toxins from the spent dialysate. The AWAK PD device requires between 1.5 and 2 litres of dialysate to perform a patient’s entire daily therapy, compared with 8 to 12 litres required by traditional PD methods.
Conducted at SGH, the single-arm pilot study enrolled 15 adults between the ages of 21 and 80 undergoing regular PD treatment. Each patient had to complete 9 dialysis sessions of 3.5 hours each with AWAK PD over three continuous days.
Preliminary results show that AWAK PD was able to efficiently remove the accumulation of waste substances from the body. Patients also did not experience any serious adverse events during dialysis with AWAK PD.
The full results from the trial are being analysed and will be announced in first half of 2019.
Suresha Venkataraya, Chief Executive Officer, AWAK Technologies, said: “We are excited by the encouraging results from this important Phase I (first-in-human) trial of AWAK PD. The findings provide positive clinical evidence of AWAK PD’s safety profile as a wearable device with the potential to truly disrupt the administration of peritoneal dialysis treatments. With the continued support of the National Medical Research Council, Singapore and Singapore General Hospital (SGH), we can now bring the technology closer to patients.
“The AWAK PD has been designed to empower ESRD patients to take control of their treatment in their own time and adapt therapy to their lifestyle rather than the other way around. We look forward to continuing our clinical work and commercialising our technology, offering an enhanced quality of life to end-stage renal disease patients worldwide.“
Dr Marjorie Foo, Principal Investigator of the AWAK PD first in human trial, said:“The number of patients with end-stage renal disease continues to climb globally, largely due to diabetes. For these patients, transplantation is the best treatment but most are on dialysis to stay alive due to the scarcity of organs. Dialysis, however, can cause much disruption to their lives. Some have even had to stop work, resulting in a loss of income.
“We are therefore heartened by the favourable results of our Phase I trial. The wearable dialysis system has the potential to not only revolutionise how peritoneal dialysis can be delivered, it also gives patients the option of ‘dialyse to live’ and not ‘live to dialyse’. This is as close as one can get to an artificial organ performing the functions of the kidney. A hospital-industry collaboration such as this is key to advancing patient care,” said Dr Foo who is also Head and Senior Consultant, Department of Renal Medicine, SGH.
Media contacts
About End-Stage Renal Disease
End stage Renal Disease (ESRD) is the fifth stage of Chronic Kidney Disease (CKD) that affects the functioning of kidneys, leading to accumulation of excess fluid and toxic wastes in the blood. People with ESRD undergo either renal transplantation or dialysis. Since renal transplantation is highly dependent on patient’s health and age, dialysis scores over as the primary treatment. It was estimated as of 2011, there were 2.7 million ESRD patients of whom 2.1 million were on dialysis. Of these 2.1 million, 10.8% of the patients are on peritoneal dialysis (PD) and the remaining 89.2% are on hemodialysis (HD)[1].
Dialysis treatment can be performed either at home, in a dialysis centre or at a hospital. In hemodialysis, blood is drawn out of the patient’s body into a synthetic filter called dialyser. In the dialyser, there are two spaces separated by a membrane, with blood passing on one side and dialysis fluid on the other side. Waste products and excess water passes from the blood through the membrane into the fluid through diffusion process. The fluid containing the waste products is then discarded while the clean blood is returned back to the patient’s body.
In peritoneal dialysis, the lining of the abdominal cavity acts like the external filter to cleanse the blood. Dialysis fluid is introduced into the abdominal cavity through a permanent tube. The fluid remains in the abdominal for a certain period of time before it is drained and discarded.
About AWAK Technologies
AWAK Technologies Pte Ltd. is a pioneering, patient-centric medical technology company with a mission to enhance the lives of dialysis patients and their caregivers by providing solutions to deliver better outcomes and improve their quality of life.
Headquartered in Singapore with an office in Burbank, California, USA, the company is dedicated to the research, development and marketing of novel, sorbent-based kidney dialysis machine for the treatment of patients with end-stage renal disease. For more information, please visit: www.awak.com
About Singapore General Hospital
Singapore General Hospital, a member of Singapore Health Services, is the public sector’s flagship hospital. Established in 1821, SGH is Singapore’s largest acute tertiary hospital with 1,700 beds and national referral centre offering a comprehensive range of 39 clinical specialties on its campus. Every year, about 1 million Singaporeans benefit from medical care delivered by its 800 specialists. As an academic healthcare institution and the bedrock of medical education, SGH plays a key role in nurturing doctors, nurses and allied health professionals, and is committed to innovative translational and clinical research in her continual strive to provide the best care and outcomes to her patients. www.sgh.com.sg
[1] Damien, P., Lanham, H. J., Parthasarathy, M., & Shah, N. L. (2016). Assessing key cost drivers associated with caring for chronic kidney disease patients. BMC Health Services Research, 16, 690. http://doi.org/10.1186/s12913-016-1922-4
SAN DIEGO and SHANGHAI, Oct. 19, 2018 /PRNewswire/ — In collaboration with Fudan University Shanghai Cancer Center and Nanfang Hospital of Southern Medical University, Singlera Genomics, a UC San Diego spinout company focused on non-invasive cancer detection, presented the results of its initial ColonES retrospective study at the 2018 American Society of Human Genetics (ASHG) Annual Meeting. ColonES utilizes targeted next-generation sequencing to screen for early stage colorectal cancer (CRC) and precancerous lesions known as advanced adenomas using methylation haplotype signatures of circulating tumor methylated DNA (ctmDNA) in blood plasma.
Detecting CRC at its earliest stages greatly improves survival rates, from 10% if detected at later stages to approximately 90% if detected earlier. “Discovering advanced adenomas, the precancerous stage of CRC, can greatly reduce the risk of CRC in the population,” said Dr. Guoxiang Cai, Professor of Surgical Oncology and Vice Director of the Department of Surgery at Fudan University Shanghai Cancer Center.“Current gold standard screening tests, such as colonoscopy or stool based tests, are uncomfortable and thus have a low compliance rate. Based on initial studies, ColonES is clearly a viable blood-based alternative which could increase CRC screening compliance.”
In the ColonES study, 1,243 patients were enrolled, including 429 healthy individuals, 204 individuals with advanced adenomas, 291 CRC stage I patients, 133 CRC stage II patients, 124 CRC stage III patients, and 102 CRC stage IV patients. These samples were matched for sex, age, neoplasm size and neoplasm location. In an independent blinded sample cohort, sensitivities of 93% for CRC and 88% for advanced adenoma were achieved with a specificity of 99%.
“These results are extremely encouraging and warrant further prospective validation,” said Yuan Gao, PhD, Cofounder and Chairman of Singlera Genomics. “The overall accuracy, cost, and convenience of ColonES could provide a viable non-invasive colon cancer screening method before colonoscopy, and ultimately save lives.”
Singlera Genomics is currently looking for collaboration partners. The company has also applied similar technology to other cancer types with high accuracy.
Fudan University Shanghai Cancer Center Fudan University Shanghai Cancer Center, established in 1931 as Sino-Belgium Radium Institute, is the first comprehensive cancer hospital in China. With a history of over eight decades, the Center has taken the initiative in exploring cancer in terms of its prevention, diagnosis, treatment, and research.
Nanfang Hospital of Southern Medical University Nanfang Hospital is the first affiliated hospital of Southern Medical University, which was founded in 1951 and became a national key university in 1979. As the earliest medical center to serve foreigners, Nanfang Hospital has admitted more than 110,000 patients from over 90 countries and regions.
Singlera Genomics Inc. (www.singlera.com) Singlera Genomics Inc., a company focusing on non-invasive genetic diagnosis, was co-founded in July 2014 in San Diego, California. The company currently has R&D centers and business operations in both La Jolla, California, and Shanghai, China. Singlera has proprietary technologies in single cell sequencing, DNA methylation, and bioinformatics.
Veeda Clinical Research Pvt. Ltd., a leading independent CRO is proud to announce that our clinical (Shivalik, Ahmedabad)and Bio analytical facilities (Insignia, Ahmedabad) successfully completed second audit by NPRA (Malaysian Regulatory agency) without anymajor or critical observations.
This Inspection was a routine study Inspection performed by the NPRA Inspectors with the purpose to verify the compliance of the facility and study conduct to the principles of Good Clinical Practices. The audit outcome confirmed that the activities in Veeda CRO are in compliance with the SOPs and regulatory guidelines.
Veeda CRO have successfully faced 50 regulatory audits in last 13 years wherein 18 USFDA Inspections were conducted successfully in last 24 months which demonstrates our commitment levels towards Quality and Regulatory Compliance.
With an enhanced focus on ‘Right First Time’ approach, Veeda CR looks forward to a brighter future in Clinical Research Arena. These inspections are another testimony to Veeda CR’s continuous quality review and improvement measures institutionalized into the work culture.
About Veeda CRO
Veeda CR is a full service CRO that conducts clinical research to support clients in their clinical programs. The company provides expert services in PK (pharmacokinetic) and PD (pharmacodynamics) studies in healthy volunteers; conducts patient trials in generic molecules and NCEs (new chemical entity) and undertakes research in Biopharmaceuticals. The company offers a fully integrated package which includes services on Phase I to Phase IV clinical trials in central nervous system, oncology, and other complex therapeutic areas. The company’s services also include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, and regulatory and medical writing to meet global clinical development needs.
SAN DIEGO and SHANGHAI, Oct. 19, 2018 /PRNewswire/ — Fudan University’s Taizhou Health Science Institute and Singlera Genomics, a UC San Diego spinout company focused on non-invasive early cancer detection, today announce initial results from the Taizhou Longitudinal Study (TLS) during the 2018 American Society of Human Genetics (ASHG) Annual Meeting. An oral presentation highlighted data showing Singlera’s PanSeer assay can detect five types of cancer up to four years before conventional diagnosis using a single blood draw.
The TLS study began in 2007 collecting plasma samples from over 120,000 healthy individuals. Study participants were monitored for a 10-year period through cooperation with local hospitals and health insurance databases, allowing longitudinal information to be collected.
Previous studies have reported that biomarker signals from early cancers are difficult to detect. By utilizing Singlera’s proprietary PanSeer assay for targeted DNA methylation haplotype next-generation sequencing, the research team was able to demonstrate early detection of colorectal, esophageal, liver, lung, and stomach cancer four years prior to disease diagnosis. These five cancer types represent 43% of cancer mortality in the US and 74% of cancer mortality in China.
“This study for the first time demonstrates non-invasive early detection of multiple types of cancer four years before conventional diagnosis,” said Yuan Gao, Ph.D., Co-founder and Chairman of Singlera Genomics. “Many cancers are detected too late for an effective treatment option to be available; by moving the date of cancer diagnosis up by several years, cancer mortality can be significantly reduced.”
“While other studies have demonstrated that solid tumors can be non-invasively detected using blood biomarkers, previous work has mostly focused on symptomatic patients that have already been diagnosed with cancer through other means,” said Li Jin, professor at Fudan University and organizer of the longitudinal study. “By combining Singlera’s unique assays with the TLS cohort, our research team was able to show that true early detection of cancer can become a reality.”
The research team is in the process of extending this early detection approach to additional cancer types, and Singlera is currently looking for collaboration partners.
Fudan University (http://www.fudan.edu.cn/en/) Fudan University, established in 1905, is located in Shanghai, China. The name “Fudan” originated from a famous statement, meaning unremitting effort. Fudan University comprises 17 full-time schools (including 66 specialties) and 69 departments across 4 campuses. It has 68 specialties for Bachelor’s Degree Candidates, 209 specialties for Master’s Degree Candidates, and 157 specialties for Doctoral Degree Candidates. It has nearly 44,300 students, including full-time students, students in Continuing Education or Network Education, as well as overseas students.
Singlera Genomics Inc. (www.singlera.com) Singlera Genomics Inc., a company focusing on non-invasive genetic diagnosis, was co-founded in July 2014 in San Diego, California. The company currently has R&D centers and business operations in both La Jolla, California, and Shanghai, China. Singlera has proprietary technologies in single cell sequencing, DNA methylation, and bioinformatics.
New image reconstruction architecture designed to support easier diagnosis to enhance workflow and user experience with innovative features and ergonomics
SINGAPORE, Oct. 21, 2018 /PRNewswire/ — Samsung Medison, a global medical equipment company and an affiliate of Samsung Electronics, is showcasing its new generation of premium ultrasound system HERA W10 and prototype of a chair-type ultrasound system HERA I10 at the 28th World Congress of the International Society of Ultrasound in Obstetrics & Gynecology (ISUOG) from October 21st to 24th in Singapore.
Samsung showcases premium new ultrasound systems ‘HERA W10’ and ‘HERA I10’ at ISUOG World Congress 2018.
HERA is a new premium platform which stands for Hyper-aperture Enhanced Reconstruction Architecture, incorporating Samsung’s new Crystal Architecture™ to provide advanced technology and capabilities with a new level of image quality. Samsung’s new platform combines Crystal Architecture™ with an advanced transducer technology called S-Vue™. It allows an 11-fold increase in processing power and 10 times the data transfer speed of Samsung’s previous system. It is expected to facilitate the examination of high-risk pregnancies and early diagnosis of abnormal fetus conditions.
“Samsung is proud to introduce a new premium ultrasound system HERA W10 and a form factor innovation ultrasound HERA I10, as well as solutions that greatly improve the efficiency of hospitals,” said Dongsoo Jun, President of Health & Medical Equipment Business at Samsung Electronics and CEO of Samsung Medison. “Samsung will continue to provide the best solutions possible and bring meaningful changes in the healthcare industry.”
New features for Samsung’s HERA W10 ultrasound system offer clinicians an optimized workflow and more information to overcome challenges, including:
Outstanding Image Quality
Crystal Architecture™ — Offers a superior image with single crystal probe technology S-Vue™, a new beamforming technology CrystalBeam™ and an advanced post-processing engine CrystalLive™.
ShadowHDR™ — Provides a shadow suppressed image, especially applicable to highly attenuated regions such as fetal head and spine.
HQ-Vision™ — Allows users get high resolution images to detect clinically important details.
New Samsung Exclusive Technologies
MV-Flow™ — Offers a detailed view of blood flow in relation to the surrounding tissues or pathology with an enhanced spatial and temporal resolution.
LumiFlow™ — Provides a three-dimensional visualization of continuous and volumic vascular image.
Seamless Workflow
Wide Control Panel — Adopted rotatable control panel with a top-notch swivel mechanism. Allows moving range of 550mm from left to right and 219mm from top to bottom.
Touch Customization — Allows users to easily change the position of the button on the touchscreen for each mode and feature.
In addition to HERA W10, Samsung is unveiling a prototype of HERA I10, which shares the same platform as HERA W10, but with a completely new ergonomic redesign. HERA I10 is a next-generation chair-type ultrasound system with a design that is entirely different from the industry norm that meets the unique needs of Ob/Gyn professionals. HERA I10 provides a comfortable experience for both the doctor and the patient by addressing the discomfort caused by the spacing and the position of the clinicians and eliminating the need for the patient to shift their body, as it automatically adjusts for proper positioning. It also reduces the force required to move the control panel back and forth and the resistance force on the wrist.
A new ultrasound solution SonoSync™ will also be introduced, which allows healthcare professionals to see real-time ultrasound scanning images in remote places[1]. SonoSync™ provides two-way communications through voice chatting and marking, improving accessibility. It can be installed on various devices such as smartphones, laptops and desktop PCs, allowing multilocation real-time training and education among healthcare professionals. Its Multiview feature also increases productivity by viewing multiple image scans in one screen.
For more information on Samsung’s healthcare division, its subsidiaries and products please visit https://www.samsunghealthcare.com.
[1] SonoSync™ may not be used for diagnostic purposes at all times. Its availability may vary in different countries, according to regulatory approvals.
About Samsung Medison
Samsung Medison is a global leading medical device company, specializing in diagnostic imaging devices. With a mission to bring health and well-being to people’s lives, the company is committed to create a new future for medical professionals and patients around the world across various medical fields. In 2011, Samsung Medison became an affiliate company of Samsung Electronics, integrating the world’s best IT, image processing, semiconductor and communication technologies into medical devices.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com.
A prototype of chair-type ultrasound system ‘HERA I10’ is being displayed at ISUOG World Congress 2018.
– Boston Consulting Group and Fortune examined 1,100 publicly traded companies in 12 months – Alphabet, Netflix, Alibaba Group Holdings were also listed in ‘Fortune Future 50’ – Continue to satisfy not only customers but also patients through innovation in health care
INCHEON, South Korea, Oct. 19, 2018 /PRNewswire/ — Samsung BioLogics, a global leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) based in South Korea, announced today that it has been ranked on Fortune’s Future 50 list of companies best positioned for strong future growth and breakout growth.
The Fortune, in partnership with Boston Consulting Group, crated ‘Future 50’ in 2017 and ranked 50 global companies with the best prospects for long-term growth.
The result is a composite of scores in four dimensions: Strategy, Technology and Investments, People, and Structure.
Alphabet, Netflix, Alibaba Group Holdings were also listed in ‘Fortune Future 50’ along with Samsung BioLogics.
Dr. T.H Kim, the president and CEO of Samsung BioLogics, said, “Positioned on ‘Fortune Future 50′ proves Samsung BioLogics’ growth potential once again just in 7 years,” and he added, “Samsung BioLogics will continue to make the full efforts to grow into a world leading biopharmaceutical drug development and manufacturing company that can help not only our customers but also our patients through continuous innovation and global market development.”
On the other hand, Samsung BioLogics’ Plant 3 became cGMP ready in October 1st, 2018. Although the company is only seven years old, it became the world’s largest CMO with total bioreactor capacity of 362,000 liters in Plant 1, 2, and 3.
In addition, Samsung BioLogics has secured CDMO contracts with 24 companies for 33 products and received 19 global manufacturing approvals as of the end of September.
Liquid biopsy drawing attention for preventing the recurrence of cancer and allowing for early detection of cancers
EDGC develops the most advanced lipuid biopsy technology
SEOUL, South Korea, Oct. 19, 2018 /PRNewswire/ — EONE-DIAGNOMICS Genome Center (EDGC), a global company in genetic analysis, has announced the release of a liquid biopsy screening service this autumn. The service is a non-invasive liquid biopsy technology which has drawn attention as the most promising advanced diagnosis technology with the development of NGS technology.
Ph.D. Sung Hoon Lee proceeded a presentation at the International Symposium of KSIO.
The liquid biopsy technology is a technology that Grail, Illumina Inc. spin-out, and others have raised about 1.8 billion dollars’ funds todevelop it. It is useful for preventing any recurrence in patients with cancer and early detection of cancer.
The liquid biopsy screening technology is known as the most advanced liquid biopsy technology that is able to early detect various cancers with a simple blood test from people without any signs or symptoms, and it is only capable through comprehensive analysis of samples, various biomarkers measurements and precise algorithms.
EDGC has been developing the liquid biopsy technology for lung cancer, colorectal cancer and breast cancer, interworking with domestic and overseas university hospitals and has decided to commercialize it as the recent clinical experiments have excellent achievements. The liquid biopsy screening service commercialized this time would be provided to the global market through CLIA certification in the United States. Also, it would predict risk of cancers statistically and detect even microscopic factors leading to cancers, analyzing both inherent risk of cancers and acquired biomarkers simultaneously.
In these regards, EDGC has presented ‘NGS Analysis Methods and Examples for Liquid Biopsy’ at the International Symposium of Korean Society of Integrative Oncology which was held in South Korea on October 14th. The symposium covered the topic of anti-cancer immunotherapy; the Nobel Prize-winning field. In the symposium, greatest scholars such as Dr. Gary Deng of the Memorial Sloan Kettering Cancer Center in the United States and Prof. Ping-Ping Li of Peking University Cancer Hospital in China participated and discussed integrated cancer treatments. Therefore, it became a valuable opportunity for EDGC to show its liquid biopsy technology.
Ph.D. Sung Hoon Lee, a chief technology officer in charge of the development for the liquid biopsy screening technology, said that the multi-omics liquid biopsy method is an innovative method to overcome constraints and limitations of existing cancer diagnosis tests by combining protein and nucleotide sequencing analysis and performing quantitative and qualitative analysis simultaneously. He explained that it is able to provide the multi-faceted service by accumulated experiences of genomic data analysis algorithms and non-invasive prenatal diagnosis that EDGC has developed so far.
Meanwhile, Variable Signal-Amplifying Algorithm (VarSAMP), a core algorithm of the technology, and Multivariant Regression are patent-pending, and other quantitative and qualitative analysis methods and complex analysis are in preparations for patents.
Also, Lee said that the method could not only detect cancers with high accuracy but also allow accurate measurement with a little data since it maximizes sensitivity but does not lower specificity. Therefore, it has an advantage to perform accurate analysis with a much lower cost as compared to methods used by overseas competitors. He expressed high confidence about it.
After announcing the technological development, EDGC plans to perform global research and additional clinical cooperation in several countries. For this, it will recruit clinical participants from South Korea, the United States, China and so on.
With this clinical participation, EDGC will promote a campaign to prepare for a healthy 100-year-old age through early detection of cancers and apprehension of comprehensive risk.
*Multi-omics: a biological analysis approach in which the data sets are multiple omes such as genome, proteome, transcriptome, epigenome and microbiome
